Physician profile
Michael D Wilcox
NPI 1891892683
$11,392.47
in general payments reported to CMS, 2019-2025
20 companies · $2,111 in 2025
The $2,111 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,457 · 2020: $1,431 · 2021: $1,327 · 2022: $1,197 · 2023: $1,868 · 2024: $2,001 · 2025: $2,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,968 · Education: $13.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,967.85 |
| Education | $13.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,602.04 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $1,549.45 | 2022-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $1,364.50 | 2019-2022 | |
| Lundbeck LLC | $1,212.25 | 2019-2025 | Rexulti |
| Corium, LLC | $1,084.69 | 2022-2025 | Azstarys, Azstarys |
| Otsuka America Pharmaceutical, INC. | $994.84 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $768.84 | 2022-2025 | Auvelity |
| Neos Therapeutics, LP | $699.55 | 2019-2025 | Adzenys Xr-Odt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $658.90 | 2020-2025 | Caplyta |
| Allergan, INC. | $393.61 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $305.69 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $187.82 | 2019-2023 | Trintellix |
| Ironshore Pharmaceuticals INC. | $143.13 | 2019-2020 | |
| Tris Pharma INC | $132.39 | 2019-2024 | Dyanavel Xr |
| Noven Therapeutics, LLC | $107.87 | 2024-2025 | Xelstrym, Secuado |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $91.23 | 2019 | |
| Eisai INC. | $51.77 | 2021 | |
| Sumitomo Pharma America, INC. | $17.88 | 2023 | Latuda |
| Janssen Pharmaceuticals, INC | $13.72 | 2025 | Spravato |
| Bausch Health US, LLC | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wilcox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.